Sr Director CMC - Islet Cell Therapy

Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Our mission at Sigilon Therapeutics is to develop improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the foreign body response (fibrosis). Treatments based on the Sigilon Therapeutics technology platform will act as responsive “living therapeutics” that can provide more natural control for diseases currently treated with intermittent injection or infusion. The company is based in Kendall Square in Cambridge, MA and is funded by Flagship Pioneering. Please forward your application via email to careers@sigilon.com

Sigilon Therapeutics is searching for an energized candidate to lead a new team focused on CMC and manufacturing a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge pancreatic islet cell technology.

Responsibilities

Sigilon Therapeutics is searching for an energized candidate to lead a new team focused on CMC and manufacturing a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge pancreatic islet cell technology. This individual would have primary responsibility for all aspects of CMC and manufacturing including: process development, analytical development, and CMC. Initial emphasis will be on partnering with the research team to create a protocol that can be transferred to a CMO. Management of the CMO relationship will be a key responsibility.  The team will have full access to all of Sigilon’s cell biology and encapsulation chemistry expertise along with substantial designated funds to enable a rapid pursuit of a very robust and competitive program.

KEY RESPONSIBILITIES

Requirements